Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial
12 February 2022 - 12:51AM
Dow Jones News
By Kimberly Chin
Regeneron Pharmaceuticals Inc. said that its eye-injection
treatment for patients with wet age-related macular degeneration, a
kind of eye disorder, met the primary endpoint in a Phase 2
trial.
The biotechnology company said an 8 mg aflibercept injection
over an extended period of time showed numeric improvements in
anatomical and vision outcomes compared with a lower dose of the
currently-approved Eylea.
Regeneron previously said that patients that received the
treatment had no retinal fluid in the macula after the 16th week,
when the primary-efficacy endpoint was being assessed.
After the 16th week, the company started administering doses
every 12 weeks.
"This is the first time we have seen a promising trend towards
sustained improved vision over Eylea in wet AMD," David Brown, the
director of research at Retina Consultants of Texas said.
The company said it will present its findings at an annual
Angiogenesis meeting on Saturday.
Regeneron expects results from a Phase 3 trial in wet
age-related macular degeneration and diabetic macular edema in the
second half of the year.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
February 11, 2022 08:36 ET (13:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2023 to Aug 2024